jimjams
Member
- Reaction score
- 0
RepliCel enters phase 2 - 2013 - great news
Everyone seen this? Looks promising.
June 11, 2012 – Vancouver, British Columbia – RepliCel Life Sciences Inc. (the “Company†or “RepliCelâ€) (OTCBB:REPCF) presented significant new data from its Phase I/IIa first-in-man clinical trial at its Annual General Meeting (“AGMâ€) of Shareholders held on Monday, June 11, 2012. To view a copy of the presentation, please click here.
David Hall, RepliCel’s President and CEO, stated, “As previously reported, a 6-month interim analysis of data from RepliCel’s first-in-man clinical trial revealed that the RepliCelâ„¢ treatment is safe and effective. This news is significant, as it allows us to move forward with our Phase II dosing trial. RepliCel’s team is working with European regulators to finalize protocols for the Phase IIb clinical trial application, expected to commence in late 2012. The Phase IIb clinical trial will be designed to optimize treatment regimen for hair growth. Several different treatment regimens will be tested, including different concentrations of cells and different treatment schedules, including single and repeat injections.†Mr. Hall further stated, “The Company is also focused on optimizing the RepliCelâ„¢ procedure with the objectives of enhancing cell yield and isolation from scalp biopsies and improving cell replication yield and processing time.â€
Over the past six months, the Company has raised over USD$2.8 million through a series of private placements. These funds will be used for the continued advancement of the RepliCelâ„¢ technology.
Source of date: http://www.replicel.com/replicel-presen ... reholders/
Everyone seen this? Looks promising.
June 11, 2012 – Vancouver, British Columbia – RepliCel Life Sciences Inc. (the “Company†or “RepliCelâ€) (OTCBB:REPCF) presented significant new data from its Phase I/IIa first-in-man clinical trial at its Annual General Meeting (“AGMâ€) of Shareholders held on Monday, June 11, 2012. To view a copy of the presentation, please click here.
David Hall, RepliCel’s President and CEO, stated, “As previously reported, a 6-month interim analysis of data from RepliCel’s first-in-man clinical trial revealed that the RepliCelâ„¢ treatment is safe and effective. This news is significant, as it allows us to move forward with our Phase II dosing trial. RepliCel’s team is working with European regulators to finalize protocols for the Phase IIb clinical trial application, expected to commence in late 2012. The Phase IIb clinical trial will be designed to optimize treatment regimen for hair growth. Several different treatment regimens will be tested, including different concentrations of cells and different treatment schedules, including single and repeat injections.†Mr. Hall further stated, “The Company is also focused on optimizing the RepliCelâ„¢ procedure with the objectives of enhancing cell yield and isolation from scalp biopsies and improving cell replication yield and processing time.â€
Over the past six months, the Company has raised over USD$2.8 million through a series of private placements. These funds will be used for the continued advancement of the RepliCelâ„¢ technology.
Source of date: http://www.replicel.com/replicel-presen ... reholders/
Last edited: